source
- Apnimed secures $192 million IPO to fund sleep-apnea drug program targeting 2027 launchApnimed, a biotech focused on sleep apnea, announced it raised $192 million through an initial public offering. The capital will be used to advance its lead drug candidate, with plans to begin a l…
- Ionis veteran scientist Frank Bennett to retire in 2027 as Recursion appoints its first AI chiefIonis announced that Frank Bennett, who joined the company as a founding scientist in 1989 and later became chief scientific officer, will retire in February 2027 after a 37-year career. Bennett’s…